PA5-23218

Perrotta P, Van der Veken B, Van Der Veken P, Pintelon I, Roosens L, Adriaenssens E, Timmerman V, Guns PJ, De Meyer GRY, Martinet W
Arteriosclerosis, thrombosis, and vascular biology 2020 May;40(5):1168-1181

ETS2 and microRNA-155 regulate the pathogenesis of heart failure through targeting and regulating GPR18 expression.

Li J, Su H, Zhu Y, Cao Y, Ma X
Experimental and therapeutic medicine 2020 Jun;19(6):3469-3478

Omega-3 Fatty Acid-Derived Resolvin D2 Regulates Human Placental Vascular Smooth Muscle and Extravillous Trophoblast Activities.

Ulu A, Sahoo PK, Yuil-Valdes AG, Mukherjee M, Van Ormer M, Muthuraj PG, Thompson M, Anderson Berry A, Hanson CK, Natarajan SK, Nordgren TM
International journal of molecular sciences 2019 Sep 7;20(18)

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry of GPR18 in Daudi cells (blue) and a matched isotype control (orange). Samples were incubated in GPR18 polyclonal antibody (Product # PA5-23218) using a dilution of 1.0 µg/mL for 30 minutes at room temperature followed by a Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight™ 550 (Product # SA5-10033). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry of GPR18 in THP-1 cells (blue) and a matched isotype control (orange). Samples were incubated in GPR18 polyclonal antibody (Product # PA5-23218) using a dilution of 1.0 µg/mL for 30 minutes at room temperature followed by a Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight™ 550 (Product # SA5-10033). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 miR-155 regulates cell viability and apoptosis through targeting GPR18 in H9c2 (2-1) cells. (A) mRNA expression levels of GPR18 were determined using reverse transcription-quantitative PCR following the overexpression and silencing of miR-155 using a mimic and inhibitor, respectively in H9c2 (2-1) cells. (B) Protein expression levels of GPR18 were determined using western blotting following the overexpression and silencing of miR-155 using a mimic and inhibitor, respectively in H9c2 (2-1) cells. (C) Cell viability of H9c2 (2-1) cells. (D) Semi-quantification of apoptosis in H9c2 (2-1) cells. (E) Apoptosis in H9c2 (2-1) cells. ** P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Differential expression analysis of GPR-18 with Resolvin D2 (RvD2) treatment. ( A ) Immunoblot analysis of placental trophoblasts (HTR-8, JAR, JEG-3 and BeWo cells) with 100 nM of RvD2 treatment for 24 h showed slight increase in the protein expression levels of GPR-18 in HTR-8 cells, however GPR-18 protein levels were unaltered with RvD2 treatment in JAR, JEG-3 and BeWo cells compared to actin as control loading. ( B ) Relative expression of GPR18 in placental trophoblasts with 100 nM RvD2 treatment for 24 h. 18S was used as a control RNA. Data are mean +- standard deviation, n = 4 experiment. * p < 0.05 vs. HTR-8 vehicle treated cells; # p < 0.05 vs. HTR-8 RvD2-treated cells; statistical comparison by ANOVA with post hoc Bonferroni correction.